Ligand Pharmaceuticals LGND Stock Issuance Proceeds
Stock Issuance Proceeds at other companies
Other financials
Where this comes from
Reported directly by Ligand Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:ProceedsFromStockOptionsExercised.
The official record: Ligand Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ligand Pharmaceuticals's stock issuance proceeds.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ligand Pharmaceuticals's stock issuance proceeds?
- Ligand Pharmaceuticals (LGND) reported stock issuance proceeds of $7.65M in Q1 2026.
- How has Ligand Pharmaceuticals's stock issuance proceeds changed year-over-year?
- Ligand Pharmaceuticals's stock issuance proceeds increased by 81.3% year-over-year, from $4.22M to $7.65M.
- What is the long-term trend for Ligand Pharmaceuticals's stock issuance proceeds?
- Over 4 years (2021 to 2025), Ligand Pharmaceuticals's stock issuance proceeds has grown at a -100.0% compound annual growth rate (CAGR), from $33.76M to $0.
- What does stock issuance proceeds mean?
- Cash received from issuing common stock — IPOs, secondary offerings, DRIP, employee stock purchase plans, and option exercises.